oxybutynin has been researched along with Atherosclerotic Parkinsonism in 3 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We previously reported the induction of catalepsy by amiodarone, aprindine and procaine, which possess a diethylaminomethyl moiety and demonstrated selective blockade of dopamine D2 receptors by these drugs in mice." | 1.31 | Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodynamic study in mice. ( Hattori, F; Inoue, N; Matsui, A; Matsuo, H; Nasu, R; Ohtani, H; Sawada, Y; Takanaga, H, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsuo, H | 1 |
| Matsui, A | 1 |
| Nasu, R | 1 |
| Takanaga, H | 1 |
| Inoue, N | 1 |
| Hattori, F | 1 |
| Ohtani, H | 1 |
| Sawada, Y | 1 |
| Zarola, F | 1 |
| Marchitto, N | 1 |
| Sindona, F | 1 |
| Pannozzi, A | 1 |
| Dalmaso, SG | 1 |
| Anticoli, S | 1 |
| Raimondi, G | 1 |
3 other studies available for oxybutynin and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodynamic study in mice.
Topics: Animals; Antitussive Agents; Benzilates; Catalepsy; Cholinergic Antagonists; Cyclopentanes; Male; Ma | 2000 |
Vascular Parkinsonism sensitive to Rotigotine therapy is found in aged patients: a clinical case description.
Topics: Aged, 80 and over; Cerebral Infarction; Dopamine Agonists; Female; Humans; Magnetic Resonance Imagin | 2018 |
Safety and efficacy of Rotigotine in hospedalized patients with Vascular Parkinsonism aged 75 and older: effects on movement, praxis capacities, time-space orientation, quality of life and adherence to medical therapy.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Brain Ischemia; Cognition; Dopamine Agonists; Fe | 2019 |